Muc5ac in pancreatic ductal adenocarcinoma
AssigneeOhio State Innovation Foundation
InventorAshish MANNE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates methods of using Mucin-5AC (MUC5AC) expression, location, and/or composition to treat, diagnose, predict, monitor, and/or track pancreatic ductal adenocarcinoma (PDA).
Claims23
A method of treating a pancreatic lesion in a subject, the method comprising:
- a) collecting a tissue sample from the subject,
- b) detecting Mucin-5AC (MUC5AC) levels in the tissue sample,
- c) classifying the subject as having a benign pancreatic lesion, a pre-cancerous pancreatic lesion, or a malignant pancreatic lesion, wherein:
- i.the benign pancreatic lesion will not express MUC5AC;
- ii.the pre-cancerous pancreatic lesion comprises increased expression of the immature MUC5AC, the mature MUC5AC, or a combination thereof, relative to a healthy control or the benign pancreatic lesion;
- and
- iii.the malignant pancreatic lesion comprises increased expression of the immature MUC5AC, mature MUC5AC, or a combination thereof, relative to the benign pancreatic lesion or the pre-cancerous pancreatic lesion, and
- d) treating the subject classified as having the benign pancreatic lesion by monitoring said subject for progression or regression of the pancreatic lesion,
- e) treating the subject classified as having the pre-cancerous pancreatic lesion by monitoring said subject for progression or regression of the lesion, or surgical resection of the pancreatic lesion, and
- f) treating the subject classified as having the malignant pancreatic lesion with at least one anti-cancer therapy comprising a chemotherapeutic agent, an imaging modality, or surgical resection.
The method of 1, wherein the benign pancreatic lesion comprises a low-risk for pancreatic ductal adenocarcinoma (PDA).
A method of decreasing expression of Mucin-5AC (MUC5AC) in a malignant pancreatic cell in a subject diagnosed with pancreatic ductal adenocarcinoma (PDA), the method comprising:
- a) collecting a tissue sample from the subject,
- b) detecting an expression level of MUC5AC in the sample relative to a control sample, and
- c) treating the subject with at least one anti-cancer therapy, wherein the anti-cancer therapy reduces the PDA and the expression level of MUC5AC in the subject relative to the control.
21-28. (canceled)
A method of preventing maturation of Mucin-5AC (MUC5AC) in a pancreatic cell in a subject diagnosed with a pancreatic lesion, the method comprising:
- a) collecting a tissue sample from a subject,
- b) detecting an immature MUC5AC, a mature MUC5AC, or a combination thereof, in the tissue sample, and
- c) treating the subject with PDA with at least one anti-cancer therapy, wherein the anti-cancer therapy prevents the immature MUC5AC from converting into the mature MUC5AC or an immunogenic MUC5AC, or wherein the anti-cancer therapy prevents the mature MUC5AC from converting into the immunogenic MUC5AC.
30-65. (canceled)
Dependencies are inferred from the claim text.